AEMCOLO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AEMCOLO (AEMCOLO).
AEMCOLO (crizotinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and mesenchymal-epithelial transition factor (MET). It inhibits ALK and ROS1 phosphorylation, blocking downstream signaling pathways involved in cell proliferation and survival.
| Metabolism | Primarily metabolized via cytochrome P450 (CYP) 3A4/5. Minor involvement of CYP2C9 and CYP2C19. |
| Excretion | Primarily fecal elimination as unchanged drug; approximately 90% of a dose is recovered in feces, with less than 1% excreted unchanged in urine. Biliary excretion accounts for the remainder. |
| Half-life | Terminal elimination half-life is approximately 18-22 hours, supporting once-daily dosing for maintained intraluminal concentrations. |
| Protein binding | Approximately 97-99% bound to albumin; negligible binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is ~0.2 L/kg, indicating minimal distribution beyond the gastrointestinal tract due to its non-systemic action. |
| Bioavailability | Oral bioavailability is less than 0.3% due to minimal systemic absorption; acts locally in the intestinal lumen. |
| Onset of Action | Oral: Clinical effect (stool consistency improvement in bile acid diarrhea) begins within 24-48 hours of first dose. |
| Duration of Action | Duration of action persists for the dosing interval of 24 hours with once-daily administration; effects on bile acid binding last throughout the day with continued dosing. |
AEMCOLO (rifamycin) delayed-release tablets: 600 mg orally twice daily for 3 days. Take with or without food.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No dose adjustment required based on GFR; pharmacokinetics not significantly altered in renal impairment. However, caution in severe renal impairment (eGFR <30 mL/min) due to limited data. |
| Liver impairment | No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); avoid use. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years; no specific weight-based dosing available. |
| Geriatric use | No specific dose adjustment; clinical trials included patients over 65 with similar efficacy and safety. Use standard dosing with monitoring for diarrhea and C. difficile infection. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AEMCOLO (AEMCOLO).
| Breastfeeding | No human data on excretion in breast milk; IgG antibodies are excreted in low amounts. M/P ratio unknown. Consider risk of infant immune suppression. Use with caution, especially in preterm neonates. |
| Teratogenic Risk | No human data; animal studies not available. Based on mechanism (GM-CSF antibody), theoretical risk of fetal immune modulation. Avoid in pregnancy unless benefit outweighs unknown risk. First trimester: unknown, potential for adverse effects. Second/third trimester: unknown. |
| Fetal Monitoring |
■ FDA Black Box Warning
AEMCOLO can cause hepatotoxicity, including fatal cases. Monitor liver function tests prior to and during treatment. Interrupt, reduce dose, or permanently discontinue based on severity.
| Serious Effects |
["Concomitant use with strong CYP3A inducers","Known hypersensitivity to crizotinib or any excipient"]
| Precautions | ["Hepatotoxicity: Includes drug-induced liver injury, can be severe.","Interstitial lung disease/pneumonitis: Can be fatal. Monitor for pulmonary symptoms.","QT interval prolongation: Increase risk of ventricular arrhythmias; avoid use with other QT-prolonging drugs.","Bradycardia: Monitor heart rate and blood pressure.","Visual disturbances: Including photopsia, blurred vision, and floaters.","Gastrointestinal perforation: Discontinue permanently.","Fetal harm: Can cause fetal harm; advise effective contraception."] |
| Food/Dietary | No significant food interactions reported. May be taken with or without food. Avoid alcohol during treatment as it may increase risk of adverse effects. |
Loading safety data…
| Monitor for signs of infection or immune-related adverse events in mother. Fetal monitoring not specifically required but standard obstetric surveillance recommended. |
| Fertility Effects | No human data; animal studies not conducted. Potential for immune modulation affecting reproductive tissues. Effect on fertility unknown. |
| Clinical Pearls | AEMCOLO (fidaxomicin) is a narrow-spectrum macrolide antibiotic indicated for Clostridioides difficile infection (CDI). It has minimal systemic absorption, achieving high fecal concentrations. It is preferred for initial episodes of severe CDI or recurrent CDI due to lower recurrence rates compared to vancomycin. Avoid use in patients with hypersensitivity to macrolides. Monitor for hypersensitivity reactions and superinfection. Not effective for systemic infections. |
| Patient Advice | Take the tablets exactly as prescribed, usually twice daily for 10 days. · Complete the full course even if you feel better to prevent relapse. · Swallow tablets whole; do not crush, chew, or break them. · If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose. · Contact your doctor if you develop severe diarrhea, abdominal pain, or blood in stool. · Inform your doctor about all medications you are taking, especially blood thinners (e.g., warfarin) as fidaxomicin may increase their effects. · Avoid alcohol during treatment. · Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing. |